Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma
CompletedOBSERVATIONAL
Enrollment
120
Participants
Timeline
Start Date
January 1, 2021
Primary Completion Date
June 1, 2022
Study Completion Date
December 30, 2022
Conditions
Immune-related Adverse EventChemotherapeutic ToxicityGastric or Gastroesophageal Junction Adenocarcinoma
Trial Locations (3)
710032
Tangdu hospital, Xi'an
Unknown
Shaanxi Provincial People's Hospital, Xi'an
Xijing hospital, Xi'an
All Listed Sponsors
lead
Xijing Hospital
OTHER
NCT06440811 - Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter